Irritable Bowel Syndrome

The Cleveland Clinic fellow explains why is upadacitinib is an essential tool in treating Crohn’s disease, especially in those who have previously failed conventional or biologic therapies.

The US Food and Drug Administration (FDA) approved linaclotide earlier this month for the treatment of patients with functional constipation aged 6-17 years.

The treatment represents the first approval for pediatric patients with functional constipation.

Kiwifruit supplementation did not have an impact on stool frequency or consistency, but magnesium oxide supplementation did result in improved stool frequency.

The linaclotide group had significant improvements from baseline in the 12 week SBM frequency rate and 12-week stool consistency.

Rates of key safety events, such as malignancies and major adverse cardiovascular events, were comparable among patients receiving placebo and ustekinumab.

Patients with IBD who were treated with advanced therapies who obtained clinical remission had 1.6 times more likely to maintain remission when compared with those who achieved clinical response without remission.

In addition, 17 female patients who completed PENFS showed improvements in various symptoms, such as pain, disability, and catastrophizing, while carbohydrate degradation and LCFA synthesis pathways decreased in the post-treatment and follow-up analysis.

The majority of patients felt it was important for healthcare providers talk to them about the symptoms, possible treatments. In addition, most patients are not prescribed a medication right away.

Previous trials using acupuncture in patients with irritable bowel syndrome have suffered from problems of high placebo response rates.

Twelve additional weeks of subcutaneous risankizumab induction was efficacious and well-tolerated in patients with Crohn's disease following an initial risankizumab 12-week induction dose.

Risankizumab induction relieved Crohn's disease symptoms and maintenance doses were effective in resolving abdominal pain, with other mixed findings for other patient-reported outcomes in the maintenance phase.

NAFLD patients had a 13% higher risk of developing IBS after multivariable adjustment compared to patients without NAFLD.

IBS-type symptoms were not linked to an increased likelihood of the need for glucocorticosteroids or flare, escalation, hospitalization, or intestinal resection.

Experts in gastroenterology share take-home messages for the management of ulcerative colitis.

David P. Hudesman, MD; Marla Dubinsky, MD; Ellen J. Scherl, MD; and Miguel Regueiro, MD, provide advice for physicians treating patients with ulcerative colitis.

Drs David P. Hudesman, Ellen J. Scherl, Marla Dubinsky, and Miguel Regueiro, explore novel therapies in the pipeline and discuss approaches to optimizing sequencing and treatment selection for ulcerative colitis.

Experts in gastroenterology discuss their approach to sequencing therapies in ulcerative colitis, considering safety, efficacy, and access to various treatment regimens and comment on challenges physicians may face when incorporating new therapies into clinical practice.

Ellen J. Scherl, MD, reviews data from the phase 3 True North study evaluating the use of ozanimod as induction and maintenance therapy for moderate to severe ulcerative colitis, and the panel shares their experience with ozanimod in clinical practice.

Ellen J. Scherl, MD, leads a discussion on challenges faced with traditional ulcerative colitis treatments.

David P. Hudesman, MD, and expert panelists provide insight on optimizing the sequencing of therapies in ulcerative colitis and determining when a change in treatment is needed.

Marla Dubinsky, MD, discusses the role of S1P receptor modulators and JAK inhibitors for the treatment of ulcerative colitis.

The mean values of stool scale form also increased in the kombucha cohort, while the control group remained unchanged.

David P. Hudesman, MD, reviews the use of anti-integrin and anti-interleukin therapies for the management of ulcerative colitis.

Ellen J. Scherl, MD, comments on the limited role of mesalamine and steroids for moderate-to-severe ulcerative colitis treatment.

Smoking was not linked to colonic transit times and colonic transit was not associated with IBS symptom severity.

Marla Dubinsky, MD, emphasizes the role of shared decision-making and patient goals of therapy when approaching treatment selection for ulcerative colitis.

Drs David P. Hudesman, Marla Dubinsky, and Ellen J. Scherl explore the impact of IBD and ulcerative colitis on a patient’s quality of life.

Ellen J. Scherl, MD, highlights the different subtypes of ulcerative colitis and the differential diagnosis with Crohn’s disease.

David P. Hudesman, MD, and Marla Dubinsky, MD, define symptoms and potential disease triggers for inflammatory bowel disease (IBD).